Publications by authors named "Maximilian Paul Schmid"
Purpose: External beam radiation therapy (EBRT), concomitant cisplatin, and magnetic resonance image guided adaptive brachytherapy performed according to the EMBRACE-II study protocol (IntErnational study on MRI-guided BRAchytherapy in locally advanced CErvical cancer) is considered state-of-the-art for the treatment of locally advanced cervical cancer. The aim of the present study was to evaluate the possibilities for realizing the planning aims and to assess the clinical outcome of using the EMBRACE-II treatment principles in real-world patients.
Methods And Materials: The EMBRACE-II treatment protocol was implemented in 2015 at Aarhus University Hospital as standard for all patients.
ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer.
Radiother Oncol
September 2023
Primary vaginal malignancies are rare, comprising only 2% of all female genital tract malignancies in adults and 4.5% in children. As part of its mission to improve the quality of care for women with gynecological cancers across Europe, the European Society of Gynaecological Oncology (ESGO) jointly with the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of Pediatric Oncology (SIOPe) developed evidence-based guidelines in order to improve the management of patients with vaginal cancer within a multidisciplinary setting.
View Article and Find Full Text PDFOverall Severe Morbidity After Chemo-Radiation Therapy and Magnetic Resonance Imaging-Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.
Int J Radiat Oncol Biol Phys
July 2023
Purpose: To evaluate overall severe late morbidity (grade ≥3) in patients with locally advanced cervical cancer treated with chemo-radiation therapy and magnetic resonance image guided adaptive brachytherapy within the prospective EMBRACE-I study, and to compare the results with published literature after standard radiograph based brachytherapy (BT).
Methods And Materials: From 2008 to 2015 the EMBRACE-I study enrolled 1416 patients. Morbidity was assessed (Common Terminology Criteria for Adverse Events version 3.
Purpose: A simple scoring system (T-score, TS) for integrating findings from clinical examination and magnetic resonance imaging (MRI) of the primary tumor at diagnosis has shown strong prognostic capability for predicting local control and survival in locally advanced cervical cancer treated with chemoradiation and MRI-guided brachytherapy (BT). The aim was to validate the performance of TS using the multicenter EMBRACE I study and to evaluate the prognostic implications of TS regression obtained during initial chemoradiation.
Methods And Materials: EMBRACE I recruited 1416 patients, of whom 1318 were available for TS.
Purpose: To qualitatively and quantitatively analyze needle visibility in combined intracavitary and interstitial cervical cancer brachytherapy on 3D transrectal ultrasound (TRUS) in comparison to gold standard MRI.
Methods And Materials: Image acquisition was done with a customized TRUS stepper unit and software (Medcom, Germany; Elekta, Sweden; ACMIT, Austria) followed by an MRI on the same day with the applicator in place. Qualitative assessment was done with following scoring system: 0 = no visibility 1 (= poor), 2 (= fair), 3 (= excellent) discrimination, quantitative assessment was done by measuring the distance between each needle and the tandem two centimeters (cm) above the ring and comparing to the respective measurement on MRI.
Background: The concept of the use of MRI for image-guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer was introduced 20 years ago. Here, we report on EMBRACE-I, which aimed to evaluate local tumour control and morbidity after chemoradiotherapy and MRI-based IGABT.
Methods: EMBRACE-I was a prospective, observational, multicentre cohort study.